Answers are grounded in this paper and cite their sources.
Aim To develop gallic acid loaded nanostructured lipid carriers (GA-NLCs) using sea buckthorn oil (SBO) for topical delivery to manage adjuvant induced rheumatic inflammation in rats.Methods Designed GA-NLCs were optimised by the Box–Behnken model and characterised by dynamic light scattering, DSC, XRD, and evaluated for drug permeation, hemocompatibility, cytocompatibility, and in vivo anti-arthritic potential.Results GA-NLCs exhibited particle size 188.4 ± 35nm, zeta potential −19.13 + 0.5 mV, entrapment efficiency 89.35 ± 2.46%, drug content 14.00 ± 1.36 mg/gm, and 87.74 ± 3.4% of drug permeation across skin. GA-NLCs showed significantly improved (p ≤ 0.05) skin enhancement ratios in comparison to gallic acid dispersion in aqueous medium (4.53 fold) and SBO (3.40 fold). GA-NLCs showed hemocompatibility and cytocompatibility. Topical application of GA-NLC gel significantly (p < 0.05) reduced arthritic score and paw edoema, comparable to diclofenac gel.Conclusion GA-NLCs exhibited enhanced skin permeation, reduced arthritic score, and synergistic anti-inflammatory effects, offering a promising intervention for the effective management of rheumatoid arthritis (RA).
No takes yet. Share an insight, caveat, or question.
Nipun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: